/Teleflex%20Incorporated%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
Headquartered in Pennsylvania, Teleflex Incorporated (TFX) designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. Valued at $11.1 billion by market cap, it leverages its expertise in vascular access, interventional cardiology, anesthesia, and urology to maintain a strong market presence, serving a broad customer base. The global medical technologies provider is expected to announce its fiscal third-quarter earnings for 2024 on Thursday, October 31, before the market opens.
Ahead of the event, analysts expect TFX to report a profit of $3.38 per share on a diluted basis, down 7.1% from $3.64 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. Its EPS of $3.42 in the recent quarter surpassed the consensus estimate by 2.7%.
